Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Deloitte
Argus Health
Citi
Merck
Fuji
Chinese Patent Office
Healthtrust
Fish and Richardson

Generated: October 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,878,972

« Back to Dashboard

Title:Compounds and methods for delivery of prostacyclin analogs
Abstract: This invention pertains generally to prostacyclin formulations and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis.
Inventor(s): Phares; Ken (Chapel Hill, NC), Mottola; David (Cary, NC)
Assignee: United Therapeutics Corporation (Silver Spring, MD)
Filing Date:Aug 17, 2016
Application Number:15/239,014
Claims:1. A compound having structure I: ##STR00031## wherein R.sup.1 is independently selected from the group consisting of H, and groups wherein OR.sup.1 are substituted or unsubstituted glycolamide esters, and wherein R.sup.2 and R.sup.3 may be the same or different and are independently selected from the group consisting of H, phosphate and groups wherein OR.sup.2 and OR.sup.3 form esters of amino acids, with the proviso that all of R.sup.1, R.sup.2, and R.sup.3 are not H; an enantiomer of the compound; or a pharmaceutically acceptable salt of the compound.

2. The compound of claim 1, wherein R.sup.1 is H.

3. The compound of claim 2, wherein at least one of R.sup.2 and R.sup.3 is phosphate.

4. The compound of claim 3, wherein each of R.sup.2 and R.sup.3 is phosphate.

5. The compound of claim 2, wherein R.sup.2 is H and R.sup.3 is phosphate.

6. The compound of claim 2, wherein R.sup.2 is phosphate and R.sup.3 is H.

7. The compound of claim 2, wherein at least one of OR.sup.2 and OR.sup.3 forms an ester of an amino acid.

8. The compound of claim 7, wherein OR.sup.2 forms an ester of an amino acid and R.sup.3 is H.

9. The compound of claim 7, wherein R.sup.2 is H and OR.sup.3 forms an ester of an amino acid.

10. A pharmaceutical composition comprising: (A) a compound having structure I: ##STR00032## wherein R.sup.1 is independently selected from the group consisting of H, substituted and unsubstituted benzyl groups, and groups wherein OR.sup.1 are substituted or unsubstituted glycolamide esters, and wherein R.sup.2 and R.sup.3 may be the same or different and are independently selected from the group consisting of H, phosphate and groups wherein OR.sup.2 and OR.sup.3 form esters of amino acids, with the proviso that all of R.sup.1, R.sup.2, and R.sup.3 are not H; an enantiomer of the compound; or a pharmaceutically acceptable salt of the compound; and (B) a pharmaceutically acceptable excipient.

11. The composition of claim 10, wherein R.sup.1 is H.

12. The composition of claim 11, wherein at least one of R.sup.2 and R.sup.3 is phosphate.

13. The composition of claim 12, wherein each of R.sup.2 and R.sup.3 is phosphate.

14. The composition of claim 11, wherein R.sup.2 is H and R.sup.3 is phosphate.

15. The composition of claim 11, wherein R.sup.2 is phosphate and R.sup.3 is H.

16. The composition of claim 11, wherein at least one of OR.sup.2 and OR.sup.3 forms an ester of an amino acid.

17. The compound of claim 16, wherein OR.sup.2 forms an ester of an amino acid and R.sup.3 is H.

18. The compound of claim 16, wherein R.sup.2 is H and OR.sup.3 forms an ester of an amino acid.

19. A method of treating pulmonary hypertension in a human subject comprising administering to a subject in need thereof an effective amount of a compound having structure I: ##STR00033## wherein R.sup.1 is independently selected from the group consisting of H, substituted or unsubstituted alkyl groups, substituted and unsubstituted benzyl groups, and groups wherein OR.sup.1 are substituted or unsubstituted glycolamide esters, and wherein R.sup.2 and R.sup.3 may be the same or different and are independently selected from the group consisting of H, phosphate and groups wherein OR.sup.2 and OR.sup.3 form esters of amino acids, with the proviso that all of R.sup.1, R.sup.2 and R.sup.3 are not H; an enantiomer of the compound; or a pharmaceutically acceptable salt of the compound.

20. The method of claim 19, wherein R.sup.1 is H.

21. The method of claim 20, wherein at least one of R.sup.2 and R.sup.3 is phosphate.

22. The method of claim 21, wherein each of R.sup.2 and R.sup.3 is phosphate.

23. The method of claim 20, wherein R.sup.2 is H and R.sup.3 is phosphate.

24. The method of claim 20, wherein R.sup.2 is phosphate and R.sup.3 is H.

25. The method of claim 20, wherein at least one of OR.sup.2 and OR.sup.3 forms an ester of an amino acid.

26. The method of claim 25, wherein OR.sup.2 forms an ester of an amino acid and R.sup.3 is H.

27. The method of claim 25, wherein R.sup.2 is H and OR.sup.3 forms an ester of an amino acid.

28. The method of claim 19, wherein said administering is performed orally.

29. The method of claim 19, wherein said administering is performed subcutaneously.

30. The method of claim 19, wherein both R.sup.2 and R.sup.3 are H.

31. The method of claim 30, wherein R.sup.1 is a substituted or unsubstituted alkyl group.

32. The method of claim 31, wherein R.sup.1 is a substituted alkyl group.

33. The method of claim 32, wherein R.sup.1 is an alkyl group in which one or more bonds to one or more carbon or one or more hydrogen atoms is replaced by a bond to an oxygen atom in a carbonyl, carboxyl or ester group.

34. The method of claim 33, wherein R.sup.1 is an alkyl group in which one or more bonds to one or more carbon or one or more hydrogen atoms is replaced by a bond to an oxygen atom in a carboxyl group.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Chubb
Healthtrust
Baxter
Chinese Patent Office
Farmers Insurance
Argus Health
Merck
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.